证券代码：600682 证券简称：南京新百 公告编号：临 2025-012 南京新街口百货商店股份有限公司 关于计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 南京新街口百货商店股份有限公司（以下简称公司）于 2025 年 4 月 28 日第十届 董事会第十七次会议审议通过了公司《关于 2024 年度计提资产减值准备的议案》，现 将相关情况公告如下： 一、计提资产减值准备情况概述 根据《企业会计准则》和会计政策的相关规定，为准确、客观地反映公司 2024 年度的财务状况及经营成果，公司对存在减值迹象的资产进行资产减值测试，2024 年度计提各项资产减值准备共计人民币 1.55 亿元，计提减值的明细情况见下表： 科目 信用减值损失（损失以"-"填列） 应收账款 -5,449.68 其他应收款 -1,141.64 小计 -6,591.32 科目 资产减值损失（损失以"-"填列） 存货 -30.08 商誉 -8,860.11 小计 -8,890.19 合计 -15,481.51 二、计提资产减值准备的具体说明 ...

关于南京新街口百货商店 股份有限公司非经营性资 金占用及其他关联资金往 来的专项说明 中名国成报字【2025】第 0073 号 审计机构：北京中名国成会计师事务所（特殊普通合伙） 地址：北京市东城区建国门内大街 18 号恒基中心一座 910 邮编：100005 目 录 关于南京新街口百货商店股份有限公司非经营性资金占用及其他 关联资金往来的专项说明 1-2 南京新街口百货商店股份有限公司 2024 年度非经营性资金占用 及其他关联资金往来情况汇总表 1-5 关于南京新街口百货商店股份有限公司 非经营性资金占用及其他关联资金往来的专项说明 中名国成报字（2025）第 0073 号 南京新街口百货商店股份有限公司全体股东： 我们接受南京新街口百货商店股份有限公司（以下简称"南京新百"）委 托，根据中国注册会计师执业准则审计了南京新百 2024 年 12 月 31 日的合并及 公司资产负债表，2024 年度合并及公司利润表、合并及公司现金流量表、合并 及公司股东权益变动表和财务报表附注，并出具了中名国成审字（2025）第 1900 号无保留意见审计报告。 根据《上市公司监管指引第 8 号—上市公司资金往来、对外担保 ...

公司代码：600682 公司简称：南京新百 南京新街口百货商店股份有限公司 2024年度内部控制评价报告 南京新街口百货商店股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况 ...

证券代码：600682 证券简称：南京新百 公告编号：临 2025-014 南京新街口百货商店股份有限公司 关于召开 2024 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 南京新街口百货商店股份有限公司（以下简称公司）已于2025年4月30日在 上海证券交易所网站（www.sse.com.cn）发布公司2024年度报告，为便于广大 投资者更全面深入地了解公司2024年度经营成果、财务状况及利润分配方案， 公司计划于2025年5月13日15:00-16:00举行2024年度业绩暨现金分红说明会，就 投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对2024年度的经营成 果、财务指标和利润分配方案的具体情况与投资者进行互动交流和沟通，在信 息披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一）会议召开时间：2025年5月13日 15:00-16:00 （二）会议召开地点：上证路演中心 （三）会议召开方式： ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 1,569,215,691.23, a decrease of 0.70% compared to CNY 1,580,283,271.46 in the same period last year[4] - Net profit attributable to shareholders was CNY 128,531,976.08, down 0.96% from CNY 129,782,239.87 year-on-year[4] - Net profit for Q1 2025 was CNY 160,470,993.98, a decrease of 3.43% from CNY 166,209,752.08 in Q1 2024[24] - The company reported a decrease in comprehensive income attributable to shareholders, totaling CNY 104,974,973.13 in Q1 2025 compared to CNY 135,300,808.40 in Q1 2024[24] - Total operating costs for Q1 2025 were CNY 1,383,758,057.31, slightly down from CNY 1,383,978,442.39 in Q1 2024[22] Cash Flow - The net cash flow from operating activities increased by 33.07% to CNY 99,159,960.87, compared to CNY 74,516,956.63 in the previous year[4] - Cash received from sales of goods and services in Q1 2025 was CNY 1,853,782,769.18, down from CNY 1,933,465,750.05 in Q1 2024[25] - The company reported a total cash inflow from operating activities of $1,971,947,687.74, compared to $2,077,882,543.61, reflecting a decrease of about 5.1%[27] - Cash inflow from investment activities totaled $119,355,403.52, down from $255,762,895.99, indicating a decline of about 53%[27] - The net cash flow from financing activities was -$11,181,459.76, slightly worse than -$10,406,142.12 in the prior period[29] Assets and Liabilities - The total assets at the end of the reporting period were CNY 26,328,731,382.77, reflecting a 0.39% increase from CNY 26,225,455,084.58 at the end of the previous year[4] - Total liabilities stood at CNY 6,047,046,655.84, slightly decreasing from CNY 6,059,290,558.34, reflecting a decline of approximately 0.20%[16] - Total liabilities as of the latest reporting period were CNY 7,097,206,230.89, a slight decrease from CNY 7,131,560,143.84[18] - The company's current assets totaled CNY 9,230,740,309.43, up from CNY 9,025,473,397.00, indicating an increase of about 2.28%[14] - The company's inventory increased to CNY 826,871,996.54 from CNY 710,835,657.86, marking a significant rise of about 16.34%[14] Shareholder Information - The equity attributable to shareholders increased by 0.60% to CNY 17,667,883,317.31 from CNY 17,562,857,384.04 at the end of the previous year[4] - The company has a total of 484,482,721 shares held by Sanbao Group Co., Ltd., representing 35.99% of the total shares[12] - The company has no significant changes in the shareholder structure, with no new major shareholders reported during the period[12] Earnings and Returns - The basic and diluted earnings per share remained unchanged at CNY 0.10[4] - The weighted average return on equity decreased slightly to 0.73% from 0.75%[4] Other Financial Metrics - Non-recurring gains and losses totaled CNY 12,264,018.95 after accounting for tax and minority interests[5] - The company reported a significant increase of 224.40% in credit impairment losses year-to-date due to provisions for bad debts[7] - Financial expenses decreased by 48.31% year-to-date, primarily due to reduced interest income[7] - The company's long-term investments remained stable at CNY 421,171,536.49, unchanged from the previous period[14]

Financial Performance - The company's total revenue for 2024 reached RMB 6,699,705,165.26, representing a 1.98% increase compared to RMB 6,569,868,788.86 in 2023[24] - Net profit attributable to shareholders decreased by 46.10% to RMB 230,073,449.45 from RMB 426,818,054.70 in the previous year[24] - Basic earnings per share fell by 46.88% to RMB 0.17 from RMB 0.32 in 2023[24] - The weighted average return on equity decreased to 1.32%, down 1.17 percentage points from 2.49% in 2023[24] - The net cash flow from operating activities increased by 13.59% to RMB 1,079,409,911.02 compared to RMB 950,231,559.25 in 2023[24] - The company's total assets as of the end of 2024 were RMB 26,225,455,084.58, a 1.97% increase from RMB 25,719,533,432.05 in 2023[24] - The net assets attributable to shareholders increased by 1.42% to RMB 17,562,857,384.04 from RMB 17,316,561,908.02 in 2023[24] - The operating costs increased by 3.70% to 3.668 billion RMB[90] - The company reported a net cash outflow from investment activities of RMB -1,085,985,699.95, a 30.21% increase in outflow compared to the previous period[105] Business Operations and Strategy - The company plans to distribute a cash dividend of RMB 0.16 per share, totaling RMB 21,426,115.54, subject to shareholder approval[6] - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[8] - The company has outlined potential risks in its future development in the management discussion and analysis section[9] - The company achieved operating revenue of 6.7 billion RMB, a year-on-year increase of 1.98%, with main business revenue accounting for 95.91% at 6.426 billion RMB[32] - The company successfully won 182 projects for its smart home care service, expanding its service reach to six new cities[34] - The company conducted 66 marketing activities throughout the year, achieving daily sales exceeding 10 million RMB on 38 occasions[32] - The company is focusing on diversifying its business and enhancing core competitiveness by leveraging its advantages in cell industry technology standards and storage scale[41] - The company has established a new subsidiary in Shenzhen to expand its business scope and enhance sustainable development capabilities[41] Research and Development - The company is focusing on expanding its research and development efforts, particularly on clinical studies related to PROVENGE, with key projects including a booster injection study and long-term survival assessments[127] - The company has initiated four investigator-initiated trials (IIT) to expand research on PROVENGE, including collaborations with Yale University and Moffitt Cancer Center[127] - The company has evaluated over 200 new product projects since 2022, focusing on developing a pipeline of immune therapy products to prepare for future growth[44] - The company is focusing on building a robust academic promotion system in collaboration with key opinion leaders in the urology oncology field[163] Market Trends and Industry Insights - The silver economy in China is currently valued at approximately 7 trillion yuan, accounting for about 6% of GDP, with projections suggesting it could reach 30 trillion yuan by 2035, representing 10% of GDP[53] - The healthcare and elderly care sectors are seeing increased government support, with a focus on developing a comprehensive elderly care service network by 2029[52] - The domestic stem cell industry has established a complete industrial chain, with the upstream sector focusing on collection and storage, while the downstream is primarily involved in transplantation and treatment[54] - The Chinese pharmaceutical market is expected to reach 1.9 trillion yuan in 2024, with an annual growth rate of approximately 7.2%, largely due to favorable policies for innovative drug access[56] - The demand for personalized elderly care services is increasing, with a focus on tailored services that meet individual health conditions and interests[157] Risks and Challenges - The company faces risks from intensified market competition, particularly in the health and elderly care sector, and will enhance its core competitiveness to mitigate these risks[180] - The company is monitoring potential risks from changes in national policies that could impact the elderly care industry, especially in overseas markets[180] - The company is addressing the risk of talent shortages in the elderly care sector by establishing training systems and improving employee retention strategies[181] - The company is adapting its operations in response to the ongoing conflict in Israel, ensuring business continuity and employee safety[182] - The company is tracking national policy changes that may affect its stem cell storage business, particularly regarding regulations and approvals[183] Corporate Governance - The company has established a comprehensive internal control system to effectively manage and control various operational risks, particularly in its numerous subsidiaries across different sectors, including retail and healthcare[195] - The board of directors consists of 11 members, with various specialized committees ensuring compliance with legal requirements and effective decision-making processes[192] - The supervisory board, comprising three members, including one employee supervisor, has been actively monitoring the board's operations and financial practices to protect shareholder interests[193] - The company emphasizes fair and transparent information disclosure, ensuring that all shareholders, especially minority shareholders, have equal access to management information[194] Future Outlook - The company anticipates continued growth in the health and elderly care industry due to the aging population and increasing demand for health services[156] - The company plans to expand its elderly care business into the UK market in 2024, aiming for significant scale growth through a replication model[168] - The company aims to enhance its core competitiveness in elderly care services by improving basic elderly care, long-term care insurance services, and digital platform operations[169] - The company plans to optimize its business structure and expand its scale and profitability by exploring new elderly care services such as community-based and ecological therapy[159]

证券代码：600682 证券简称：南京新百 公告编号：临 2025-006 南京新街口百货商店股份有限公司 关于2024年度日常关联交易执行情况暨 2025年度日常关联交易预计情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 2025 年 4 月 28 日，公司第十届董事会第十七次会议以 8 票同意、0 票反对、 0 票弃权，审议通过了公司《关于 2024 年度日常关联交易执行情况暨 2025 年度 日常关联交易预计情况的议案》。该议案涉及关联交易，关联董事生德伟先生、 关联董事袁千惠女士、关联董事吴刚先生对该项议案回避表决。该议案在提交董 事会审议前，已经公司独立董事 2025 年第一次专门会议审议通过。 公司第十届监事会第四次会议以 3 票同意、0 票反对、0 票弃权，审议通过 了公司《关于 2024 年度日常关联交易执行情况暨 2025 年度日常关联交易预计情 况的议案》。 该议案尚需提交公司年度股东大会审议。 （二）2024 年度日常 ...

证券代码：600682 证券简称：南京新百 公告编号：临 2025-010 南京新街口百货商店股份有限公司 2025年第一季度经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 南京新街口百货商店股份有限公司（以下简称公司）根据上海证券交易所《上市 公司自律监管指引第 3 号——行业信息披露》之《第四号——零售》的相关要求，现 将公司 2025 年第一季度主要经营数据（未经审计）公告如下： 一、2025 年第一季度主要经营数据如下： （一）主营业务分行业情况 | | | | 主营分行业 | 主营业务收入 | 主营业务成本 | 毛利率 | 营业收入比上年 | 营业成本比上年 | | --- | --- | --- | --- | --- | --- | | | | | （%） | 增减（%） | 增减（%） | | 商业 | 99,731,067.35 | 31,402,919.65 | 68.51 | -11.31 | -2.76 | | 宾馆餐饮业 | 7,801,100.36 | 1,058,679.29 | 8 ...

4月29日，南京新百（600682）发布2024年年度报告，公司报告期内实现营业收入67.00亿元，同比上涨 1.98%，归属于上市公司股东的净利润2.30亿元。公司同时发布的2025年一季报显示，1—3月实现营收 15.69亿元，归属于上市公司股东的净利润1.29亿元。南京新百大健康业务仍占主导地位，2024全年持续 稳健增长，并披露了2024年度ESG报告，坚持可持续高质量发展。 生物医疗方面，2024年，齐鲁干细胞继续实施多元化发展策略，在现有的脐血干细胞保存服务基础上持 续创新推出多室保存服务，以及包括免疫细胞储存和检测在内的多样化产品与服务；公司全资子公司济 南科阅医学检验实验室有限公司开展健康与衰老评估、AD检测等项目，并在深圳设立了深圳卓元干细 胞工程有限公司，扩大业务范围。2024年，齐鲁干细胞全力推进国际细胞治疗认证基金会FACT认证， 并已于2025年2月成为国内首家获得FACT国际认证的细胞机构。这一里程碑标志着齐鲁干细胞的技术实 力与质量管理体系跻身全球领先行列，也意味着我国细胞治疗领域迈入国际标准化新阶段。 2024年，丹瑞美国不断强化PROVENGE作为早期无症状或轻微症状的mCR ...